Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer with peritoneal metastasis: Status quo and how should we proceed

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer... editorial memo (2020) 13:363–364 https://doi.org/10.1007/s12254-020-00655-4 Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer with peritoneal metastasis: Status quo and how should we proceed Ingmar Königsrainer © Springer-Verlag GmbH Austria, part of Springer Nature 2020 Metastatic disease in colorectal cancer (CRC) is a chal- CRS ± HIPEC will play a significant role in the future lenging multidisciplinary disease, nowadays, embrac- [4]. New innovative trial designs as proposed in the ing all oncological disciplines. article from Yurtas et al. [5] may be needed, based on In selected patients, radical surgery is an oppor- the difficulty of creating a prospective study, including tunity for curing patients or important to “chronify” potent intravenous chemotherapy regimens. disease. This was clearly shown for years in metastatic The present uncertainty about HIPEC in CRC with liver disease from CRC. PM in the community should not lead to abandon- In peritoneal metastasis (PM) surgery has become ment of this multimodal treatment approach, but a dominant key in selected patients reaching a me- strengthen the important role of surgery in this dis- dian overall survival of over 40 months [1]. The role of ease and proceed to redefine the role of HIPEC. hyperthermic intraperitoneal chemotherapy (HIPEC), http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer with peritoneal metastasis: Status quo and how should we proceed

Download PDF
2 pages

Loading next page...
 
/lp/springer-journals/cytoreductive-surgery-and-hyperthermic-intraperitoneal-chemotherapy-N9YNeENcqo
Publisher
Springer Journals
Copyright
2020 Springer-Verlag GmbH Austria, part of Springer Nature
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-020-00655-4
Publisher site
See Article on Publisher Site

Abstract

editorial memo (2020) 13:363–364 https://doi.org/10.1007/s12254-020-00655-4 Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer with peritoneal metastasis: Status quo and how should we proceed Ingmar Königsrainer © Springer-Verlag GmbH Austria, part of Springer Nature 2020 Metastatic disease in colorectal cancer (CRC) is a chal- CRS ± HIPEC will play a significant role in the future lenging multidisciplinary disease, nowadays, embrac- [4]. New innovative trial designs as proposed in the ing all oncological disciplines. article from Yurtas et al. [5] may be needed, based on In selected patients, radical surgery is an oppor- the difficulty of creating a prospective study, including tunity for curing patients or important to “chronify” potent intravenous chemotherapy regimens. disease. This was clearly shown for years in metastatic The present uncertainty about HIPEC in CRC with liver disease from CRC. PM in the community should not lead to abandon- In peritoneal metastasis (PM) surgery has become ment of this multimodal treatment approach, but a dominant key in selected patients reaching a me- strengthen the important role of surgery in this dis- dian overall survival of over 40 months [1]. The role of ease and proceed to redefine the role of HIPEC. hyperthermic intraperitoneal chemotherapy (HIPEC),

Journal

memo - Magazine of European Medical Oncology – Springer Journals

Published: Dec 1, 2020

Keywords: oncology; medicine/public health, general

References

  • A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7
    F Quenet, D Elias, L Roca, D Goere, L Ghouti, M Pocard
  • Should patients with peritoneal carcinomatosis of colorectal origin with synchronous liver metastases be treated with a curative intent? A case-control study
    L Maggiori, D Goéré, B Viana, D Tzanis, F Dumont, Ch Honoré, C Eveno, D Elias
  • Patient selection for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in colorectal cancer
    P Horvarth, I Königsrainer
  • Do we still need CRS and HIPEC in colorectal cancer in times of modern chemotherapy and immunotherapy?
    E Gasser, P Kogler, A Lorenz, R Kafka-Ritsch, D Öfner, A Perathoner
  • Löffer MW. Cytoreductive surgery and HIPEC in colorectal cancer—did we get hold of the wrong end of the stick?
    C Yurttas, OM Fisher, D Cortés-Guiral, SP Haen, IA Königsrainer, S Beckert, W Liauw